[Exacerbation of psoriasis during alpha-interferon therapy].
In three female patients with metastasising malignant melanoma psoriasis exacerbated during the third week of treatment with recombinant interferon-alpha-2b, at a weekly dosage of three times 10 million IU. The psoriatic lesions vanished almost completely after discontinuing the drug and systemic administration of corticosteroids. It appears that induction of psoriasis exacerbation is yet another important side effect of interferon, at least at elevated doses, whereas low alpha-interferon dosage levels may improve psoriasis in nononcological patients.
Hartmann
F
F
Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover.
von Wussow
P
P
Deicher
H
H
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000150:complications / Q000628:therapy; D011565:Psoriasis / Q000209:etiology* / Q000473:pathology; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000150:complications / Q000628:therapy; D013997:Time Factors
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Psoriasis-Exazerbation bei Therapie mit alpha-Interferon.